title: Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial.
abstract: OBJECTIVE
  To compare dual therapy (omeprazole and amoxicillin) with triple therapy (omeprazole, amoxicillin, and clarithromycin) in the treatment of Helicobacter pylori infection. The efficacy of 1 mg/kg/day omeprazole was randomly compared with 2 mg/kg/day.
  
  
  METHODS
  252 patients (median age, 11.0 years; range, 3-18) presenting with chronic abdominal pain underwent endoscopy and a 13C-urea breath test. Gastric biopsy specimens were taken for histological examination and for the rapid urease test. Patients were treated for two weeks: group A (n = 63) received amoxicillin (50 mg/kg; maximum, 2 g/day), group B (n = 73) received amoxicillin and clarithromycin (20 mg/kg; maximum, 1 g/day). Both groups were randomly treated with either 1 or 2 mg/kg omeprazole (maximum, 80 mg/day). Diagnostic procedures were repeated four weeks after the end of treatment.
  
  
  RESULTS
  11 patients were excluded; 136 patients were H pylori positive (56%), 105 of whom were re-examined after treatment. Helicobacter pylori was eradicated in 52% of group A and 83% of group B. The dose of omeprazole had no influence on the eradication rate. Specificity and sensitivity of the rapid urease test were 94% and 93%, respectively. Specificity and sensitivity of the 13C-urea breath test were 93% and 95%, respectively.
  
  
  CONCLUSIONS
  Dual therapy can no longer be recommended. Triple therapy is more effective than dual therapy in the eradication of H pylori infection. The lower dose of 1 mg/kg omeprazole was as effective as 2 mg/kg.
authors.affiliation: Department Pediatric Gastroenterology, University of Erlangen, Loschgestr. 15, D-91054 Erlangen, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Behrens
authors.forename: T
authors.initials: T
authors.lastname: Lang
authors.forename: K M
authors.initials: KM
authors.lastname: Keller
authors.forename: L
authors.initials: L
authors.lastname: Bindl
authors.forename: M
authors.initials: M
authors.lastname: Becker
authors.forename: B
authors.initials: B
authors.lastname: Rodeck
authors.forename: P
authors.initials: P
authors.lastname: Küster
authors.forename: G F
authors.initials: GF
authors.lastname: Wündisch
authors.forename: M
authors.initials: M
authors.lastname: Stolte
mesh_terms: D000293:Adolescent; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole